NICE seeks uro/gynae expert for interventional procedures committee:
This article was originally published in Clinica
The Interventional Procedures Advisory Committee (IPAC) of the UK's National Institute for Health and Clinical Excellence (NICE) is seeking an expert in gynaecology or urogynaecology to replace a member who is stepping down in September. IPAC assesses R&D evidence to advise NICE on the safety and efficacy of new or rare interventional (surgical, endoscopic and radiological) procedures. The recommendations form the basis of NICE's guidance on these for the NHS in the whole of the UK. The closing date for applications is September 14 2007, and should be sent to Interventional Procedures Programme associate director Mirella Marlow (firstname.lastname@example.org).
You may also be interested in...
Emcure’s Tillomed has been forced to withdraw its application for a version of doxorubicin, in light of the EMA taking a closer look at medicines for which study data prepared by Panexcell Clinical Laboratories was used to support marketing authorization applications.
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.